BioCardia Will Present CardiAMP Trial in Phoenix
The medical technology firm will share trial design details at the Heart Failure Society of America meeting.
Updated on Oct. 8, 2026 in Heart Disease
Live Poll
Should the FDA fast-track approval for experimental cell therapies to treat chronic heart failure?
BioCardia will present the design for its CardiAMP HF II clinical trial during the Heart Failure Society of America Annual Scientific Meeting starting October 9, 2026, in Phoenix. The presentation will outline the study of high-dose autologous cell treatment for patients with ischemic heart failure.
Why it matters
The study aims to determine the efficacy of a cell therapy system for patients with reduced ejection fraction who are already receiving guideline-directed medical therapy. Positive results could provide the necessary evidence for future regulatory submissions to both the FDA and Japan's PMDA.
The CardiAMP HF II trial evaluates high-dose autologous cell treatment in patients with ischemic heart failure and reduced ejection fraction. The FDA has indicated that data from this trial may be sufficient to support future approval.
The players
BioCardia
Headquartered in Sunnyvale, California, this firm develops regenerative medicine and cardiovascular medical devices.
Heart Failure Society of America
This professional organization is dedicated to the advancement of heart failure research and clinical care standards.
FDA
This federal agency is responsible for regulating medical devices and therapies in the United States.
PMDA
The Pharmaceuticals and Medical Devices Agency is the Japanese regulatory body responsible for drug and medical device approvals.
The details
BioCardia plans to share the study details through a scientific poster presentation during the meeting. The firm also scheduled sessions to discuss the evidence supporting this therapy with heart failure care leaders.
Timeline
March 24, 2026: BioCardia filed its Form 10-K with the SEC.
October 7, 2026: BioCardia announced the upcoming scientific poster presentation.
October 9 - 12, 2026: The HFSA Annual Scientific Meeting takes place in Phoenix.
The Big Picture
This presentation is a key milestone for the CardiAMP cell therapy system clinical trials currently undergoing regulatory evaluation. It marks a critical step in establishing the evidence base required to transition from investigational status to potential market approval.
For patients with ischemic heart failure, this trial represents a potential expansion of available treatment options beyond standard medical therapy. If approved, this autologous cell treatment could offer a new approach to managing reduced ejection fraction.
The takeaway
The presentation highlights ongoing efforts to refine regenerative treatment protocols for chronic heart failure. Patients should consult with their cardiologists regarding how emerging clinical trial data might influence future care options.
Further reading
Learn more about the latest innovations in Heart Disease management and research.
More information
View the latest company updates and clinical research details on the BioCardia company website.
Live Poll
Should the FDA fast-track approval for experimental cell therapies to treat chronic heart failure?
